WebJun 6, 2024 · This partnership combines TwinStrand’s proven duplex sequencing solution with Singular’s HD-Seq™ technology on the G4 Sequencing Platform to maximize mutation detection sensitivities for applications such as monitoring measurable residual disease (MRD)SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems Inc. … WebTwinStrand Biosciences 3,772 followers on LinkedIn. Ultra-rare variants are detected with unparalleled sensitivity and specificity with TwinStrand Duplex Sequencing We are a …
Development of a Universal Assay for Minimal Residual Disease in …
WebThe TwinStrand Duplex Sequencing AML MRD assay was used to sequence a serially-diluted mixture of AML mutation-containing DNA to a duplex depth >1,000,000x. Target clones … WebMay 6, 2024 · New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life ... exotic name
TwinStrand Biosciences to Showcase Recent Applications of its …
WebJun 6, 2024 · TwinStrand DuplexSeq™ AML-29 Minimal Residual Disease (MRD) Assays offer high-sensitivity detection of ultra-low frequency mutations in acute myeloid leukemia … WebAML-MRD Featured Posters AACR 2024 Duplex Sequencing for MRD Detection in Acute Myeloid Leukemia Download Additional Posters ASH 2024 Duplex Sequencing with … WebMar 4, 2024 · TwinStrand launched their technology with four new assays at the Advances in Genome Biology and Technology (AGBT) conference on Marco Island, FL, February 23-26. Specifically, they presented the use of their technology to measure residual disease in acute myeloid leukemia (AML MRD) and mutagenesis in human, mouse, and rat models. bts cute selfies